This is precisely my issue with our PR, what you posted here is from Punit's blog, this is exciting. THIS is the kind of language that should be in the f-ing PR. Outside of us on this board, no one will see this. The broad market sees that we're collaborating with a university and if they look hard enough they'll see Merck's name mentioned once.
$ONCS totally awesome Melanoma P2B Combo with Merck's KEYTRUDA® (pembrolizumab), and exactly what we have been expecting. At last the dream is fulfilled and now recruitment details will follow.